Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.

@article{Tadori2005AripiprazolesLI,
  title={Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.},
  author={Yoshihiro Tadori and Takashi Miwa and Katsura Tottori and Kevin D. Burris and Arlene D. Stark and Toyoki Mori and Tetsuro Kikuchi},
  journal={European journal of pharmacology},
  year={2005},
  volume={515 1-3},
  pages={10-9}
}
Aripiprazole is the first clinically approved atypical antipsychotic agent having dopamine D2 receptor partial agonist activities. To evaluate aripiprazole's agonist and antagonist properties, we established a Chinese hamster ovary cell line expressing high and low densities of the long and short isoforms of human dopamine D2 receptors, then compared its properties with 7-{3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy}-2(1H)-quinolinone (OPC-4392), S(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…